| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/18/2007 | CA2626961A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| 05/18/2007 | CA2626446A1 Compounds and compositions as ppar modulators |
| 05/18/2007 | CA2626443A1 Oxazole and thiazole ppar modulators |
| 05/18/2007 | CA2624703A1 Extracts from the bark of corynanthe species, use thereof, and medicaments, dietary products, and pharmaceutical preparations containing said extracts |
| 05/18/2007 | CA2590511A1 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor |
| 05/17/2007 | US20070112205 Cyanopyrrolidine derivatives |
| 05/17/2007 | US20070112059 Cyanopyrrolidine derivatives |
| 05/17/2007 | US20070112046 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors |
| 05/17/2007 | US20070112040 Amino nicotinate derivatives as glucokinase (GLK) modulators |
| 05/17/2007 | US20070112028 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide |
| 05/17/2007 | US20070111945 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action |
| 05/17/2007 | US20070111942 For detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 05/17/2007 | US20070111940 Peptide agonists of GLP-1 activity |
| 05/17/2007 | US20070110834 Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity |
| 05/17/2007 | US20070110833 Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity |
| 05/17/2007 | US20070110800 Pharmaceutical composition having uniform drug distribution and potency |
| 05/16/2007 | EP1785492A2 Process for preparing docosahexaenoic acid and docosapentaenoic acid |
| 05/16/2007 | EP1785424A2 Fused 1,2,4-triazoles and pharmaceutical uses thereof |
| 05/16/2007 | EP1785144A2 Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 05/16/2007 | EP1785142A1 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds |
| 05/16/2007 | EP1785138A1 Mitochondria activators |
| 05/16/2007 | EP1785137A1 Remedy for hyperlipemia |
| 05/16/2007 | EP1785134A2 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 05/16/2007 | EP1785132A1 Constitutional function-improving agents |
| 05/16/2007 | EP1784504A2 Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
| 05/16/2007 | EP1784391A1 Phenanthridine carbonyl phenols as cytokine expression modulators |
| 05/16/2007 | EP1784223A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 05/16/2007 | EP1784207A1 Ica512 couples insulin secretin and gene expression in beta cells |
| 05/16/2007 | EP1784201A2 Physiologically active composition |
| 05/16/2007 | EP1784195A1 Pharmaceutical composition comprising galactose, selenium, vitamin e and/or phosphatidyl choline, and pharmaceutical uses of galactose |
| 05/16/2007 | EP1784191A1 Treatment of psychological and cognitive disorders using a cholesterol-lowering agent in combination with an antidepressant |
| 05/16/2007 | EP1784188A2 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 05/16/2007 | EP1784184A2 The use of n-aryl diazaspiracyclic compounds in the treatment of addiction |
| 05/16/2007 | EP1684752B1 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists |
| 05/16/2007 | EP1569634B1 Use of a ppar-alpha agonist and metformin for the treatment of obesity |
| 05/16/2007 | EP1465638B1 Phosphate transport inhibitors |
| 05/16/2007 | EP1458883B1 Screening method for agents useful in treating diabetes |
| 05/16/2007 | EP1455605B1 Soft drink replacer |
| 05/16/2007 | EP1305285B1 N-substituted indoles useful in the treatment of diabetes |
| 05/16/2007 | EP1265900B1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d|pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| 05/16/2007 | EP1165603B1 Human neurogenin 3-encoding nucleotide sequences |
| 05/16/2007 | EP1085896B1 Conformationally constrained backbone cyclized somatostatin analogs |
| 05/16/2007 | EP0989853B1 Self-regulated apoptosis of inflammatory cells by gene therapy |
| 05/16/2007 | CN1964989A Long lasting insulin derivatives and methods thereof |
| 05/16/2007 | CN1964984A Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof |
| 05/16/2007 | CN1964966A Rosiglitazone phosphate and polymorphic forms |
| 05/16/2007 | CN1964956A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 05/16/2007 | CN1964955A Small molecules for treatment of hypercholesterolemia and related diseases |
| 05/16/2007 | CN1964948A Therapeutic agents |
| 05/16/2007 | CN1964703A Immediate release pharmaceutical tablets with height greater than width |
| 05/16/2007 | CN1962695A GLP-1 infusion proteins, their preparation and use |
| 05/16/2007 | CN1962682A American waerplantain triterpenoidal alcohol extract and its preparation method |
| 05/16/2007 | CN1962661A Folacin dimethylbiguanide and process for production thereof |
| 05/16/2007 | CN1962596A Ketone compounds and compositions for cholesterol management and related uses |
| 05/16/2007 | CN1961876A Use of phthalimide derivative in preparation of medicament for resisting angiogenesis |
| 05/16/2007 | CN1961857A Equipment for processing health calcium powder and method for processing the calcium powder thereby |
| 05/16/2007 | CN1961746A Clinical enternal nutrition made from halobios |
| 05/16/2007 | CN1961734A Method for preparing yam dumpling |
| 05/16/2007 | CN1961715A Fox fur nutrition enhancer |
| 05/16/2007 | CN1961699A A fat-reducing health tea and preparation method thereof |
| 05/16/2007 | CN1316021C Nerve growth factor cDNA, clone and expression of Chinese cobra |
| 05/16/2007 | CN1315865C Loguat leaf total dehydrocamphenilic acid and its preparation method and use |
| 05/16/2007 | CN1315847C 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 05/16/2007 | CN1315835C Polycyclic guanine phosphodiesterase v inhibitors |
| 05/16/2007 | CN1315833C Azaindole kinase inhibitors |
| 05/16/2007 | CN1315832C Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives |
| 05/16/2007 | CN1315822C Quinoline derivatives having VEGF inhibiting activity |
| 05/16/2007 | CN1315813C 2-amino-4h-3,1-benzoxazin-4-one derivatives for the treatment of obesity |
| 05/16/2007 | CN1315809C Quinoline derivatives and their use as 5-HT6 ligands |
| 05/16/2007 | CN1315770C Method and device for producing formic acid formates and use of said formates |
| 05/16/2007 | CN1315473C Therapeutic compositions |
| 05/16/2007 | CN1315452C Pharmaceutical dosage form and method of making |
| 05/16/2007 | CN1315413C Compositions for appetite control and related methods |
| 05/16/2007 | CN1315409C Materials and method for the treatment or prevention of obesity |
| 05/15/2007 | US7217738 β2-adrenergic receptor agonists |
| 05/15/2007 | US7217732 Cannabinoid receptor agonists |
| 05/15/2007 | US7217724 2-[(2-hydroxy-2-pyridinylethyl)amino]ethyl-substituted indoles, e.g., N,N-Diethyl-2-{3-[(2R)-2-((2R)-2-hydroxy-2-pyridin-3-ylethylamino)-propyl]-1H-indol-7-yloxy}acetamide; beta 3-adrenoceptor stimulants, used for treating obesity, hyperglycemia, frequent urination, and urinary incontinence |
| 05/15/2007 | US7217719 1,3,8-Triaza-spiro[4.5]decan-2-one compounds, e.g., (4S)/(4R)-4-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-8-methyl-1,3,8-triaza-spiro [4.5]decan-2-one; treating schizophrenia, psychosis, migraine, hypertension, thrombosis, vasospasm, depression, anxiety, sleep and eating disorders |
| 05/15/2007 | US7217711 Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions |
| 05/15/2007 | US7217706 Benzocycloheptenylamino derivatives; treatment of pollakiuria or urinary incontinence |
| 05/15/2007 | US7217697 Sodium dependent glucose transporter 1 inhibitors; blocking small intestine absorption of glucose; diabetes |
| 05/15/2007 | US7217694 Inhibitors of IAPP fibril formation and uses thereof |
| 05/15/2007 | US7217692 Complex of a human FOXC2 protein and a FOXC2-interacting protein |
| 05/15/2007 | US7217687 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 05/15/2007 | CA2437844C Method for increasing leptin levels using nicotinic acid compounds |
| 05/15/2007 | CA2392973C Benzoimidazole derivatives useful as antiproliferative agents |
| 05/15/2007 | CA2127445C Nutrient composition |
| 05/10/2007 | WO2007053846A1 Compositions of hoodia gordonii and pinolenic acid derivatives |
| 05/10/2007 | WO2007053662A1 Dihydroisoindolones as allosteric modulators of glucokinase |
| 05/10/2007 | WO2007053657A1 Substituted pyrrolones as allosteric modulators of glucokinase |
| 05/10/2007 | WO2007053503A1 Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| 05/10/2007 | WO2007053406A1 Combinations of antihypertensive and cholesterol lowering agents |
| 05/10/2007 | WO2007053345A1 Glucokinase activators |
| 05/10/2007 | WO2007052843A1 Heterocyclic amide compound and use thereof |
| 05/10/2007 | WO2007052794A1 o-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG |
| 05/10/2007 | WO2007052592A1 Pharmaceutical preparation having excellent photostability |
| 05/10/2007 | WO2007051847A1 Tricyclo substituted amides as glucokinase modulators |
| 05/10/2007 | WO2007051846A1 Tricyclo substituted amides |
| 05/10/2007 | WO2007033266A3 Dipeptidyl peptidase inhibitors for treating diabetis |
| 05/10/2007 | WO2007031291A3 Foodstuff additive |